Events & Presentations

Featured Events
Date Event Details Remind Me
11/15/2016
4:30 PM
Stifel 2016 Healthcare Conference
Speaker: Rachel King, CEO
11/17/2016
1:20 PM
Jefferies 2016 London Healthcare Conference
Speaker: Rachel King, CEO
Upcoming Event
Date Event Details Remind Me
03/07/2017
10:00 AM ET
Cowen and Company 37th Annual Health Care Conference
Speaker: Rachel King, CEO
Email
X

Cowen and Company 37th Annual Health Care Conference

Email Reminder

Please sign up for email alert notification.

Archived Events
Date Event Details
12/05/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 4049-Poster Session, A Phase I/II Study of GMI¬1271, a Novel E¬Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date
12/05/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 3826-Poster Session, E¬Selectin Antagonist GMI¬1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Absrtact 2823-Poster Session, Vascular E-Selectin Protects Leukemia Cells from Chemotherapy By Directly Activating Pro-Survival NF-Kb Signaling - Therapeutic Blockade of E-Selectin Dampens NF-Kb Activation
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 3519-Poster Session, Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograph Murine Model
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 2826-Poster Session, dministration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 2509-Poster Session, Rivipansel (GMI-1070) Inhibits E-Selectin Recognition of Sialyl LewisX Activation and Arrest of Human Neutrophils Expressed on CD62L (L-selectin) and Blocks Integrin
12/04/2016
7:30 AM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract #270-Rivipansel, A Small Pan-Selecting Antagonist Improves Cerebral Perfusion and Inhibits Leukocyte Adhesion and in Murine Sickle Cell Disease Model
11/11/2016
12:00 PM ET
Society for Immunotherapy of Cancer Meeting
Speaker: Abstract 209
09/08/2016
Glycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care

Today, GlycoMimetics joins leading patient advocacy groups, researchers, clinicians, policymakers, industry, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research both in the United States and globally. The newly formed Sickle Cell Disease Coalition’s first order of business is an international call to action to change the status quo of SCD. 

Click here for more information

08/11/2016
2:30 PM ET
Canaccord Genuity 36th Annual Growth Conference
06/09/2016
9:30 AM
Jefferies 2016 Healthcare Conference
Speaker: Brian Hahn, CFO
03/08/2016
8:00 AM ET
Cowen and Company 36th Annual Health Care Conference
02/08/2016
3:00 PM
Biotechnology Industry Organization 2016 BIO CEO & Investor Conference
Speaker: Rachel King, CEO
02/04/2016
GlycoMimetics CFO Brian Hahn Among New Members of SEC's Advisory Committee on Small and Emerging Companies Members

The Securities and Exchange Commission has announced the members of its Advisory Committee on Small and Emerging Companies, including Brian Hahn, CFO of GlycoMimetics.  The advisory committee was established in 2011 and has been renewed twice for additional terms.  The renewed committee will hold its first meeting on Thursday, February 25.

More information can be found at: https://www.sec.gov/news/pressrelease/2016-22.html

12/02/2015
Biotech Leader Provides Testimony Before House Capital Markets Subcommittee

Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc., provided testimony today on behalf of the Biotechnology Industry Organization (BIO) before the House Subcommittee on Capital Markets and Government Sponsored Enterprises. Hahn serves as the Co-Chair of BIO’s Finance & Tax Committee.

More information can be found at http://www.businesswire.com/news/home/20151202005977/en/Biotech-Leader-Testimony-House-Capital-Markets-Subcommittee

12/01/2015
GlycoMimetics CSO John Magnani Receives Society for Glycobiology President's Innovator Award

At the 2015 Society for Glycobiology Annual Meeting on December 1, GlycoMimetics Vice President and Chief Scientific Officer John Magnani, Ph.D., was presented with the President's Innovator Award. In accepting the award, Dr. Magnani also provided a lecture to meeting attendees on "The Discovery and Development of Glycomimetic Drugs for Cancer and Inflammatory Disease." Dr. Magnani is an expert in glycobiology having identified and characterized many carbohydrate tumor antigens, such as CA19-9, and developed fundamental technology for the identification of functional carbohydrate epitopes. 

More information can be found at: http://www.glycobiology.org/files/2015_preliminary_program.pdf

11/19/2015
3:20 PM UK
Jefferies 2015 London Healthcare Conference
Speaker: Rachel King, CEO
11/17/2015
11:45 AM ET
Stifel 2015 Healthcare Conference
Speaker: Rachel King, CEO
08/12/2015
5:00 PM
Canaccord Genuity 35th Annual Growth Conference
07/30/2015
Biotech Nation Radio Podcast Featuring GlycoMimetics CEO Rachel King
07/23/2015
Nature Biotechnology's First Rounder's Podcast Featuring GlycoMimetics CEO Rachel King
06/25/2015
GlycoMimetics CEO Rachel King Featured on The Worldview 100 Most Influential People in Biotech List

GlycoMimetics CEO Rachel King recently was listed on the Scientific American Worldview 100 Most Influential People in Biotech List. Worldview brought together leaders in biotechnology and biosciences along with other experts in contributing areas to create this list.

From Rachel’s listing – “In her testimony to the U.S. Senate Committee on Small Business and Entrepreneurship on March 19, 2015, King eloquently distilled the relationship between science and business: 'Patents allow biotech inventions of great societal value to be passed or shared among parties best suited to unlock their potential at any given stage of development and commercialization—each contributing its part, each sharing the risk of failure, each increasing the odds that a product eventually reaches patients.'

06/17/2015
GlycoMimetics CEO Rachel King Speaks at the BIO2015 Convention as Outgoing BIO Board Chair

View the Video

06/01/2015
11:00 AM ET
Jefferies 2015 Global Healthcare Conference
Speaker: Rachel King, CEO
04/12/2015
GlycoMimetics CMO Helen Thackray Presents on Rivipansel at Sickle Cell Disease Symposium/Meeting

At the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting, which was sponsored by the Foundation for Sickle Cell Disease Research, GlycoMimetics CMO Helen Thackray presented on "Defining Clinical Benefit in Sickle Cell Anemia: Results From the Rivipansel (GMI-1070) Phase 2 Program." Dr. Thackray presented during the conference's 3rd Investigational Drug Symposium, held Sunday April 12.  
More information on her session and additional information about the event can be found at: https://www.eventbrite.com/e/click-here-9th-annual-sickle-cell-disease-research-and-educational-symposium-and-38th-national-registration-13848666735.

03/30/2015
GlycoMimetics CEO Rachel King Keynoted Maryland Regional Biotech Forum

GlycoMimetics CEO Rachel King presented the keynote address during the first day of the inaugural Maryland Regional Biotech Forum. Speaking on "The Evolution of a Company in the Context of the Evolution of a Biotech Ecosystem," Ms. King offered the story of GlycoMimetics (to date) and reviewed her own experiences watching the advancement of the Maryland region's biotech community since 1989. During the presentation, Ms. King stressed to the 300 registered event attendees that a company and community's values contribute to their ultimate success. Stressing the importance of developing new drugs for people living with illness and disease, she added, "The work we do in biotech deserves the best we can bring to it!"

03/20/2015
GlycoMimetics CEO Rachel King Testifies Before U.S. Senate as BIO's Chair

BIO's Chair and CEO of GlycoMimetics Rachel King testified before the U.S. Senate Committee on Small Business and Entrepreneurship where she reinforced the need for patent protection incentives to encourage small business innovation. Ms. King also encouraged Congress to address weaknesses in the United States Patent and Trademark Office's Inter Partes Review (IRP) system that allows abuses perpetrated against legitimate patent holders. Read more at http://www.biotech-now.org/public-policy/patently-biotech/2015/03/bio-chair-testifies-before-senate

03/02/2015
2:10 PM
Cowen & Co. 35th Annual Healthcare Conference
Speaker: Rachel King, CEO
02/09/2015
3:00 PM ET
2015 BIO CEO & Investor Conference
Speaker: Rachel King, CEO
11/18/2014
3:00 PM
Stifel 2014 Healthcare Conference
Speaker: Brian Hahn, CFO
10/07/2014
1:30 PM PT
13th Annual BIO Investor Forum
Speaker: Rachel King, CEO
10/07/2014
12:00 PM PT
13th Annual BIO Investor Forum - Opening Plenary Lunch: A High-Speed Option at the FDA: Lessons from Veterans of the Breakthrough Therapy Designation Process
Speaker: Rachel King and panelists, CEO
09/26/2014
9:00 AM ET
NewsMakers in the Biotech Industry
Speaker: Rachel King, CEO
08/14/2014
1:30 PM ET
Canaccord Genuity 34th Annual Growth Conference
Speaker: Rachel King, CEO
07/07/2014
Sickle Cell Drug Passes Early Phase Trial
(SACRAMENTO, Calif.)

A potentially groundbreaking investigational drug designed to treat the painful vaso-occlusive crises that are the hallmark of sickle cell disease has been found to be safe following a clinical trial at UC Davis.

For additional information:

http://www.ucdmc.ucdavis.edu/publish/news/newsroom/9061

07/03/2014
New Drug Gives Hope to Sickle Cell Anemia Patients

For additional information please view here.

06/26/2014
Rachel King, GlycoMimetics at the 2014 BIO International Convention

Rachel King, Chair of the Biotechnology Industry Organization CEO of GlycoMimetics, discusses the biggest issues facing BIO members this year.

06/25/2014
GlycoMimetics CEO Rachel King Participated in BIO2014 Super Session: EY 2014 Biotechnology Industry Report

GlycoMimetics CEO Rachel King was part of a Super Session at the 2014 Biotechnology Industry Organization 2014 International Convention focused on the state of the biotech industry and how companies must still focus on improving the efficiency of R&D in the face of limited resources. EY’s 2014 biotechnology industry report, as described during the session, explores approaches that allow companies to “unlock value” by conducting R&D in ways that are both more capital-efficient and better aligned with the need to demonstrate value. Two E&Y representatives served as moderators of the session and Rachel was joined on the panel by Mara Aspinall, Ventana Medical Systems Inc.; Philip Birth, Aptiv Solutions; and Brian Daniels, Bristol-Meyers Squibb.

06/24/2014
BIO Elects New Board Members and Officers for the 2014-2015 Term

SAN DIEGO, Jun 23, 2014 (BUSINESS WIRE) -- The Biotechnology Industry Organization (BIO) is pleased to announce the re-election of Rachel King, President & CEO, GlycoMimetics, Inc., as the Chair of its Board of Directors for the 2014-2015 term, the election of Dan Junius, President & CEO, ImmunoGen, as its new Board Treasurer, and the re-election of David Pyott, Chairman, President & CEO, Allergan, Inc., as Board Secretary. The Board also elected 19 of its Directors to serve on BIO’s Board Executive Committee for the new term. In addition, BIO welcomes the election of 10 new members to its Board of Directors, voted upon at this year’s 2014 BIO International Convention .

“We welcome our new officers and Board members, and are looking forward to working with them to create a more favorable policy, legislative and business development environment for the global biotech industry,” said Jim Greenwood, BIO President & CEO. “This newly-constituted Board of Directors brings significant industry experience and passion that will serve BIO and its members well.”

Click here for press release.

06/03/2014
10:00 AM - 10:30 AM ET
Jefferies 2014 Global Healthcare Conference
Speaker: Rachel King, CEO
04/09/2014
Brian Hahn of GlycoMimetics Testifies at Congressional Hearing on Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies

On April 9, the House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled "Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies." Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.

Read BIO's Press Release

03/13/2014
9:30 AM - 9:55 AM
Barclays Global Healthcare Conference 2014
Speaker: Rachel King , CEO
02/23/2014
BioCentury TV: Spotlight on Sickle Cell Disease, Featuring GlycoMimetics CEO Rachel King
02/18/2014
GlycoMimetics CFO Brian Hahn Joined Sourcefire CFO for Tech Council of Maryland's Panel - "The Stories of Two Deals Straight from the CFOs"

On February 18, 2014, the Tech Council of Maryland held a panel during its Financial Executive Forum breakfast. GlycoMimetics CFO Brian Hahn along with Sourcefire CFO Todd Headley talked about the two companies' recent business deals and where the market is headed. 

“It was a lively discussion about the company and how the markets have been hotter than we’ve seen in years,” said Hahn.  “I had a chance to talk about GLYC’s IPO process and how our licensing agreement with Pfizer played into the story for Wall Street investors as we became a public company.”

Afternoon of 02/11/2014
1:30 PM - 1:55 PM ET
BIO CEO & Investor Conference
Speaker: Rachel King, Chief Executive Officer
Location: Waldorf Astoria - New York City
01/20/2014
GlycoMimetics Featured as NASDAQ's First IPO of 2014
Add to Briefcase = add file to Briefcase